Zevra Therapeutics, Inc. (ZVRA)
(Delayed Data from NSDQ)
$4.65 USD
-0.02 (-0.43%)
Updated May 31, 2024 04:00 PM ET
After-Market: $4.66 +0.01 (0.22%) 7:06 PM ET
3-Hold of 5 3
F Value F Growth C Momentum F VGM
Brokerage Reports
0 items in cart
Zevra Therapeutics, Inc. [ZVRA]
Reports for Purchase
Showing records 21 - 28 ( 28 total )
Company: Zevra Therapeutics, Inc.
Industry: Medical - Drugs
2Q23: IH Data Arimoclomol NDA in 2H23, Ample Funds Provide Flexibility
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Zevra Therapeutics, Inc.
Industry: Medical - Drugs
Company: Zevra Therapeutics, Inc.
Industry: Medical - Drugs
1Q23: IH Data Arimoclomol NDA in 2023, Ample Funds Provide Flexibility
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Zevra Therapeutics, Inc.
Industry: Medical - Drugs
Will Run Several Small Phase 1s Before Furthering KP1077 In Narcolepsy
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Zevra Therapeutics, Inc.
Industry: Medical - Drugs
Company: Zevra Therapeutics, Inc.
Industry: Medical - Drugs
New SDX Patent Issued, Helps Found Sleep Data Initiative Data Platform
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Zevra Therapeutics, Inc.
Industry: Medical - Drugs
Company: Zevra Therapeutics, Inc.
Industry: Medical - Drugs
4Q22: Data Coming in 2023, Funding Into 2026 Provides Ample Flexibility
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J